Generics increase competition: study
The study by an MIT professor and Analysis Group researchers reportedly confirmed that the increase in generics had not reduced incentives to challenge brand name patents.
The OPDP has only issued two letters in 2017, compared to 11 last year.
The federal government alleged that the drugmaker instructed its sales reps to convey messages to doctors that downplayed the drug's safety risks.
The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.